CFN
DNA icon

Cordasco Financial Network’s Ginkgo Bioworks DNA Stock Holding History

Cordasco Financial Network’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$0 Buy
+5
New +$610 ﹤0.01% 589

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Cordasco Financial Network's DNA Position: Q2 2022 in Review

Cordasco Financial Network opened a new position in Ginkgo Bioworks (DNA) in Q2 2022: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #589 among its holdings.

260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

  • Cordasco Financial Network held 5 shares of Ginkgo Bioworks worth $0 as of Q2 2022.
  • Ginkgo Bioworks was a new Cordasco Financial Network position in Q2 2022.
  • Ginkgo Bioworks made up ﹤0.01% of Cordasco Financial Network's portfolio in Q2 2022, its #589 holding.
  • 260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on Cordasco Financial Network's 13F filing for Q2 2022, filed 15 Jul 2022.